TherapeuticsMD, Inc. (TXMD): Nasdaq/NYSE listing notice — TXMD receives Nasdaq deficiency notice for missing annual meeting; has 45 days to submit compliance plan
TherapeuticsMD, Inc.
Received Nasdaq deficiency letter on Jan 6, 2023 for failing to hold 2022 annual meeting within 12 months of FYE Dec 31, 2021.
No immediate effect on listing; TXMD has until Feb 20, 2023 to submit a plan to regain compliance.
If plan accepted, Nasdaq may grant extension until June 29, 2023 to hold annual meeting.
Company intends to submit a plan and hold the 2022 annual meeting before June 29, 2023.
If plan rejected, TXMD can appeal to a Hearings Panel; listing would remain pending decision.
TherapeuticsMD, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).
Exchange
nasdaq
Notice
deficiency notice
Rules
5620(a)
Exact text from the filing
January 6, 2023, TherapeuticsMD, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it was not in compliance with the rules for continued listing as set forth in Nasdaq Listing Rule 5620(a) (the “Annual Meeting Rule”) due to the Company’s failure to hold an annual meeting of stockholders within 12 months after its fiscal year ended December 31, 2021. The Notice has no immediate effect on the listing of the Company’s common stock, par value $0.001 per share (“Common Sto
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.